This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
HAYES, Inc. Ketamine infusion for treatment-resistant bipolar depression. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017
Bipolar disorder is a chronic illness characterized by alternating periods of profound depression and excessively elevated or irritable mood (mania). These episodes of extreme mood are interspersed by periods of relatively normal mood. Bipolar disorder is a severely impairing illness associated with unemployment, decreased productivity, and excess mortality.
Ketamine therapy for bipolar disorder often involves infusing a subdissociative dose of ketamine hydrochloride intravenously. Patients are awake during the procedure, but an anesthesiologist or other qualified healthcare professional is often present for patient monitoring since ketamine is typically used as a dissociative anesthetic. Pretreatment workup may include psychological testing and treatment history, pregnancy testing, and toxicology screening since ketamine can interact with other drugs. There is little postinfusion care beyond
monitoring for psychotomimetic effects and holding for observation if the side effects are severe. Multiple ketamine infusion sessions may be necessary.
The available medications for bipolar disorder have limited effect during a depressive phase and carry some safety concerns. Ketamine represents a safe drug that can rapidly reduce depressive symptoms and may be a viable option for bipolar patients during a severe depressive phase. Bipolar patients need to be monitored
closely following infusion of ketamine because the relief of depressive symptoms may trigger a
Does ketamine reduce or eliminate the symptoms of treatmentresistant bipolar depression? How does ketamine compare with other strategies for treating treatment-resistant bipolar depression? Is ketamine a safe therapy for treatment-resistant bipolar depression? Have definitive patient selection criteria been established for use of ketamine as a therapy for treatment-resistant bipolar depression?
Subject indexing assigned by CRD
Bipolar Disorder; Depressive Disorder, Treatment-Resistant; Humans; Ketamine
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: firstname.lastname@example.org
Date abstract record published